EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment

Stefan S Bielack iD, Carole Soussain iD, Christopher P Fox iD, Caroline Houillier iD, Thais Murciano iD, Wendy Osborne iD, Pier Luigi Zinzani iD, Carmelo Rizzari iD, Stefan Schwartz iD

Journal of Cancer Research and Clinical Oncology · 2024-10-02 · 150 (10)

DOI: 10.1007/s00432-024-05945-6 ↗

At a glance

Übersichtsarbeit in Journal of Cancer Research and Clinical Oncology, published online on 2024-10-02. Written by Stefan S Bielack and 8 co-authors. Institution: Paediatrics 5 (Oncology, Haematology, Immunology), Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany. Major MEDLINE topics: Methotrexate, gamma-Glutamyl Hydrolase, Leucovorin. Cited 30 times so far (Crossref); 73 references. The full text is freely available (open access, CC BY 4.0). Funded by: Charité - Universitätsmedizin Berlin.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

High-dose methotrexate (HDMTX) is used in the treatment of a range of adult and childhood cancers. Although HDMTX can provide effective anti-tumor activity with an acceptable safety profile for most patients, delayed methotrexate elimination (DME) develops in a minority of patients receiving HDMTX and may be accompanied by renal dysfunction and potentially life-threatening toxicity. A panel of European physicians with experience in the use of HDMTX as well as of glucarpidase convened to develop a series of consensus statements to provide practical guidance on the prevention and treatment of DME, including the use of glucarpidase. Robust implementation of supportive measures including hyperhydration and urine alkalinization emerged as critical in order to reduce the risk of DME with HDMTX treatment, with leucovorin rescue critical in reducing the risk of DME complications. Early recognition of DME is important to promptly implement appropriate treatment including, intensified hydration, high-dose leucovorin and, when appropriate, glucarpidase.

Subjects

MeSH terms (MEDLINE)

Methotrexategamma-Glutamyl HydrolaseLeucovorinHumansAntimetabolites, AntineoplasticEuropeNeoplasmsRecombinant Proteins

Author keywords

CarboxypeptidasesConsensusDelayed methotrexate eliminationGlucarpidaseMethotrexate pharmacokineticsMethotrexate toxicity

Substances

Methotrexategamma-Glutamyl HydrolaseLeucovoringlucarpidaseAntimetabolites, AntineoplasticRecombinant Proteins

Authors and institutions

  • Paediatrics 5 (Oncology, Haematology, Immunology), Klinikum Stuttgart - Olgahospital, Stuttgart Cancer Centre, Stuttgart, Germany.
  • Service d'Hématologie, Institut Curie, Paris, France.
  • School of Medicine, University of Nottingham, Nottingham, UK.
  • Department of Neurooncology, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France.
  • Pediatric Oncology and Hematology Service, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Department of Haematology, Newcastle Upon Tyne NHS Foundation Trust, and Newcastle University, Newcastle Upon Tyne, UK.

ORCID profiles: Stefan S Bielack, Carole Soussain, Christopher P Fox, Caroline Houillier, Thais Murciano, Wendy Osborne, Pier Luigi Zinzani, Carmelo Rizzari, Stefan Schwartz

Funding

  • Charité - Universitätsmedizin Berlin

Cite

APA

Bielack, S. S., Soussain, C., Fox, C. P., Houillier, C., Murciano, T., Osborne, W., Zinzani, P. L., Rizzari, C., & Schwartz, S. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology, 150(10). https://doi.org/10.1007/s00432-024-05945-6

Vancouver

Bielack SS, Soussain C, Fox CP, Houillier C, Murciano T, Osborne W, et al. A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology. 2024;150(10). doi:10.1007/s00432-024-05945-6

BibTeX
@article{Bielack2024,
  author = {Bielack, Stefan S and Soussain, Carole and Fox, Christopher P and Houillier, Caroline and Murciano, Thais and Osborne, Wendy and Zinzani, Pier Luigi and Rizzari, Carmelo and Schwartz, Stefan},
  title = {A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  volume = {150},
  number = {10},
  doi = {10.1007/s00432-024-05945-6}
}
Start for free →